CoChat

A story of the potential effect of non-steroidal anti-inflammatory drugs (NSAIDs) in Parkinson’s disease: beneficial or detrimental effects

The DOI matches its Crossref record; the references it cites are not checked yet.

Abstract

Parkinson's disease (PD) is an advanced neurodegenerative disease (NDD) caused by the degeneration of dopaminergic neurons (DNs) in the substantia nigra (SN). As PD is an age-related disorder, the majority of PD patients are associated with musculoskeletal disorders with prolonged use of analgesic and anti-inflammatory agents, such as non-steroidal anti-inflammatory drugs (NSAIDs). Therefore, NSAIDs can affect PD neuropathology in different ways. Thus, the objective of the present narrative review was to clarify the potential role of NSAIDs in PD according to the assorted view of preponderance. Inhibition of neuroinflammation and modulation of immune response by NSAIDs could be an effective way in preventing the development of NDD. NSAIDs affect PD neuropathology in different manners could be beneficial or detrimental effects. Inhibition of cyclooxygenase 2 (COX2) by NSAIDs may prevent the development of PD. NSAIDs afforded a neuroprotective role against the development and progression of PD neuropathology through the modulation of neuroinflammation. Though, NSAIDs may lead to neutral or harmful effects by inhibiting neuroprotective prostacyclin (PGI2) and accentuation of pro-inflammatory leukotrienes (LTs). In conclusion, there is still a potential conflict regarding the effect of NSAIDs on PD neuropathology.

Overview

Integrity signals

Registry

Crossref · 10.1007/s10787-023-01192-2

Cites

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

The citation lists are queued

They are fetched later and appear here then.

References 184 · Cited by 47

Research works printed but not linked: 6

  1. Al-kuraishy HM, Al-windy SA (2013) Experimental antibacterial activity of selective cyclooxygenase antagonist. Int J Pharm Chem Biol Sci 3(3):692–699
  2. Batiha GE-S, Al-Kuraishy HM, Al-Gareeb AI, Elekhnawy E (2022) SIRT1 pathway in Parkinson’s disease: a faraway snapshot but so close. Inflammopharmacology 29:1–20
  3. Ling Q-l, Murdoch E, Ruan K-H (2016) How can we address the controversies surrounding the use of NSAIDS in neurodegeneration? Future Sci 8:1153–1155
  4. Ramazani E, Tayarani-Najaran Z, Fereidoni M (2019) Celecoxib, indomethacin, and ibuprofen prevent 6-hydroxydopamine-induced PC12 cell death through the inhibition of NFκB and SAPK/JNK pathways. J Basic Med Sci 22:477
  5. Schwartz M, Ziv Y (2008) Immunity to self and self-maintenance: what can tumor immunology teach us about ALS and Alzheimer’s disease? Trends Pharmacol. Sci 29:287–293
  6. Zarghi A, Arfaei S (2011) Selective COX-2 inhibitors: a review of their structure-activity relationships. Iranian J Pharm Res 10:655

Metadata

Authors
Alrouji, M., Al-Kuraishy, H. M., Al-Gareeb, A. I., Saad, H. M., & Batiha, G. E.-S.
Affiliations
  • Shaqra University (SA)
  • Mustansiriyah University (IQ)
  • Matrouh University (EG)
  • Damanhour University (EG)
Corresponding author
  • Alrouji, Mohammed
  • Al-Kuraishy, Hayder M.
  • Al-Gareeb, Ali I.
  • Saad, Hebatallah M.
  • Batiha, Gaber El-Saber
Venue
Inflammopharmacology
Published
2023-03-24
Volume
31
Issue
2
Pages
673-688
ISSN
  • 0925-4692 (ISSN-L)
  • 1568-5608
OpenAlex
W4360809405
Cited by
47
References
184
Citations by year
2026: 10 · 2025: 15 · 2024: 15 · 2023: 7
FWCI
1.91
Type
journal article
Language
en
Open access
closed
Licence
Locations
  • Inflammopharmacology (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
  • Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
  • Health Sciences › Medicine › Pharmacology (medical) › Inflammatory mediators and NSAID effects
Keywords
Parkinson's disease, nonsteroidal anti-inflammatory drugs, neuroinflammation, COX-2 inhibition, prostacyclin, leukotrienes, neuroprotection, dopaminergic neuron loss, substantia nigra, neurodegenerative diseases, musculoskeletal disorders
MeSH terms
Neuroinflammatory Diseases, Anti-Inflammatory Agents, Anti-Inflammatory Agents, Non-Steroidal, Humans, Parkinson Disease, Neuroprotective Agents, Neurodegenerative Diseases

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: A story of the potential effect of non-steroidal anti-inflammatory drugs (NSAIDs) in Parkinson’s disease: beneficial or detrimental effects. https://app.cochat.ai/papers/10.1007/s10787-023-01192-2
The paper
Alrouji, M., Al-Kuraishy, H. M., Al-Gareeb, A. I., Saad, H. M., & Batiha, G. E.-S. (2023). A story of the potential effect of non-steroidal anti-inflammatory drugs (NSAIDs) in Parkinson’s disease: beneficial or detrimental effects. Inflammopharmacology. https://doi.org/10.1007/s10787-023-01192-2

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.